Core Viewpoint - Aojing Medical (688613) has experienced a decline in stock price and performance metrics, with significant changes in shareholder structure and upcoming corporate actions [1][2][3][4]. Stock Performance - As of August 29, 2025, Aojing Medical's stock closed at 20.0 CNY, down 4.4% from the previous week [1]. - The stock reached a high of 21.26 CNY and a low of 19.15 CNY during the week [1]. - The company's current market capitalization is 2.74 billion CNY, ranking 115th in the medical device sector and 4666th in the A-share market [1]. Financial Performance - For the first half of 2025, Aojing Medical reported a main revenue of 100 million CNY, a slight decrease of 0.2% year-on-year [2]. - The net profit attributable to shareholders was 7.9753 million CNY, down 13.52% year-on-year [2]. - The second quarter of 2025 showed a main revenue of 57.5772 million CNY, an increase of 8.88% year-on-year, with a net profit of 6.9338 million CNY, up 203.59% year-on-year [2]. Shareholder Changes - As of June 30, 2025, the number of shareholders increased to 8543, reflecting an 8.07% rise since March 31, 2025 [1]. - The average number of shares held per shareholder decreased from 17,100 to 16,000, with an average holding value of 306,600 CNY [1]. Corporate Announcements - Aojing Medical's second supervisory board meeting on August 29, 2025, approved several key proposals, including the half-year report and the use of idle fundraising for operational needs [3]. - A special shareholders' meeting is scheduled for September 15, 2025, to discuss the re-election of a non-independent director [3]. - BioVeda China RMB Investment Limited, holding 5.28% of the company, plans to reduce its stake by up to 1% between September 22 and December 22, 2025 [4].